These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25499223)

  • 1. TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
    Kim YH; Choi YW; Han JH; Lee J; Soh EY; Park SH; Kim JH; Park TJ
    Neoplasia; 2014 Dec; 16(12):1107-20. PubMed ID: 25499223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF-Oncogene-Induced Senescence and the Role of Thyroid-Stimulating Hormone Signaling in the Progression of Papillary Thyroid Carcinoma.
    Moulana FI; Priyani AAH; de Silva MVC; Dassanayake RS
    Horm Cancer; 2018 Feb; 9(1):1-11. PubMed ID: 29209896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.
    Choi YW; Kim HJ; Kim YH; Park SH; Chwae YJ; Lee J; Soh EY; Kim JH; Park TJ
    Exp Mol Med; 2014 Nov; 46(11):e120. PubMed ID: 25378232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
    Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
    PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
    Lee JU; Huang S; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Kim SY; Joung KH; Kim JM; Shong M; Jo YS
    Eur J Endocrinol; 2012 Jul; 167(1):93-101. PubMed ID: 22535643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
    Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
    Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
    Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.
    Lee J; Seol MY; Jeong S; Kwon HJ; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Lee EJ; Chung WY; Jo YS
    J Mol Endocrinol; 2015 Apr; 54(2):115-24. PubMed ID: 25608512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
    Myklebust LM; Akslen LA; Varhaug JE; Lillehaug JR
    Thyroid; 2011 Nov; 21(11):1217-25. PubMed ID: 22007921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
    Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).
    Leonardi GC; Candido S; Carbone M; Raiti F; Colaianni V; Garozzo S; Cinà D; McCubrey JA; Libra M
    Mol Med Rep; 2012 Oct; 6(4):687-94. PubMed ID: 22858857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of BRAF and its extracellular signal-regulated kinase 1/2 signal pathway in papillary thyroid cancer].
    Yi W; Zhong D; Zou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 37(9):889-94. PubMed ID: 23000762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.